Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | CTSL | P07711 | 1/20 | 0.31 |
| ▸ | CTSB | P07858 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23101911 | 0.88 | TSHR (0.34) | PIK3CD | |
| SCHEMBL19058762 | 0.82 | CYP1A2 (0.46) | MAPTCYP1A2CTSLCTSBCTSK | |
| SCHEMBL18858384 | 0.79 | PIK3CD (0.36) | PIK3CD | |
| SCHEMBL19038153 | 0.74 | CYP1A2 (0.48) | MAPTCYP1A2CTSLCTSBCTSK | |
| SCHEMBL11677049 | 0.73 | ALDH1A1 (0.47) | MAPTCYP1A2CTSLCTSBCTSK | |
| SCHEMBL22500128 | 0.73 | ALDH1A1 (0.47) | MAPTCYP1A2CTSLCTSBCTSK | |
| SCHEMBL11677487 | 0.73 | ALDH1A1 (0.47) | MAPTCYP1A2CTSLCTSBCTSK | |
| SCHEMBL2102512 | 0.72 | MAPT (0.34) | MAPTEPHX1 | |
| SCHEMBL18945598 | 0.72 | MAPT (0.34) | MAPT | |
| SCHEMBL102262 | 0.72 | PIK3CD (0.45) | PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264404-A1 | Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of cns disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264404-A1 | Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of cns disorders | GRIN2C, GRIN2B, PMP22 | MAPT 223/4885CYP1A2 103/4885PIK3CD 2836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.